{"filing":{"accession_number":"0001140361-26-040388","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-20","primary_document":"ef20084189_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/ef20084189_8k.htm"},"events":[{"id":36765,"run_id":33897,"accession_number":"0001140361-26-040388","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"FDA approval of HIBSAGO (bepirovirsen), a first-in-class hepatitis B treatment licensed from Ionis to GSK in 2019, represents a significant regulatory and commercial milestone for Ionis. Ionis is eligible for regulatory and sales milestone payments plus tiered royalties of 10-12% on net sales, materially affecting the company's future revenue streams and pipeline value.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41282,"accession_number":"0001140361-26-040388","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of HIBSAGO (bepirovirsen), a drug developed by Ionis's partner GSK, for treating chronic hepatitis B. This represents a significant regulatory and commercial milestone for Ionis's pipeline—the drug was licensed from Ionis to GSK in 2019, and Ionis is eligible for regulatory and sales milestone payments plus tiered royalties of 10-12% on net sales. While this is material to investors as a major product approval affecting future revenue streams, it does not fit the specific categories of earnings release, M\u0026A activity, or other defined event types; it is best classified as an operational/strategic milestone in the company's business development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:34:02.749192+00:00","company_name":"","ticker":null,"filing_date":""},{"id":41283,"accession_number":"0001140361-26-040388","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"GSK's FDA approval of HIBSAGO (bepirovirsen), a drug licensed from Ionis, represents a significant regulatory and commercial milestone for Ionis' pipeline. While the approval itself is GSK's announcement, Ionis discloses it as a material development affecting its business prospects and future royalty streams (10-12% tiered royalties on net sales plus additional milestone payments). This is a transformative regulatory achievement for a first-in-class medicine with unprecedented functional cure rates, but it does not fit neatly into earnings_release (no financial results disclosed), ma_activity (no acquisition/merger), or other specific categories. It is clearly operational/strategic in nature—a product development milestone with commercial implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:34:02.749192+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41282,"accession_number":"0001140361-26-040388","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of HIBSAGO (bepirovirsen), a drug developed by Ionis's partner GSK, for treating chronic hepatitis B. This represents a significant regulatory and commercial milestone for Ionis's pipeline—the drug was licensed from Ionis to GSK in 2019, and Ionis is eligible for regulatory and sales milestone payments plus tiered royalties of 10-12% on net sales. While this is material to investors as a major product approval affecting future revenue streams, it does not fit the specific categories of earnings release, M\u0026A activity, or other defined event types; it is best classified as an operational/strategic milestone in the company's business development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:34:02.749192+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-10-21"},{"id":41283,"accession_number":"0001140361-26-040388","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"GSK's FDA approval of HIBSAGO (bepirovirsen), a drug licensed from Ionis, represents a significant regulatory and commercial milestone for Ionis' pipeline. While the approval itself is GSK's announcement, Ionis discloses it as a material development affecting its business prospects and future royalty streams (10-12% tiered royalties on net sales plus additional milestone payments). This is a transformative regulatory achievement for a first-in-class medicine with unprecedented functional cure rates, but it does not fit neatly into earnings_release (no financial results disclosed), ma_activity (no acquisition/merger), or other specific categories. It is clearly operational/strategic in nature—a product development milestone with commercial implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:34:02.749192+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-10-21"}]}